Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dynavax Technologies Corporation
Dynavax Announces Fourth Quarter and Year-End 2008 Financial Results
March 18th, 2009
Dynavax Technologies Corporation (Nasdaq: DVAX) reported financial results for the fourth quarter and year ended December 31, 2008 and provided a corporate update and financial outlook for 2009. “We are making progress in our discussions with the regulatory authorities in the United States and Europe regarding the development of HEPLISAVTM, our Phase 3 hepatitis B vaccine that has demonstrated significant clinical benefits based on our trials,” commented Dino Dina, M.D., President and Chief Executive Officer of Dynavax. “Our pharmaceutical partnerships, funding agreements, and stringent management of our cash provide Dynavax with the resources to reach several value...
Source: Vaccine Weekly (2009-03-18)
|
